No abstract

Purpose TACE is the standard-of-care for patients with intermediate stage HCC whilst the multi-kinase inhibitor sorafenib improves survival in patients with advanced disease. The TACE 2 trial was designed to determine whether TACE + sorafenib improves progression free survival (PFS) compared to TACE + Placebo. Patients and methods Patients were randomised 1:1 to continuous sorafenib (400mg BD) or placebo combined with TACE using drug-eluting beads (DEB-TACE) performed 2-5 weeks post-randomisation. Further DEB-TACE was performed according to radiological response and patient tolerance. Inclusion criteria included unresectable, liver

No abstract

No abstract

No abstract